Liver International · Nov 16, 2026

Clinical Impact of the AISF STEPS ‐ MASH Algorithm: Real‐World Application in Tertiary Hepatology Practice

By Pugliese N, D'Ambrosio R, Armandi A et al.

Background and Aims: The approval of resmetirom and semaglutide for non‐cirrhotic people living with metabolic dysfunction‐associated steatohepatitis (MASH) and significant fibrosis has created a need for pragmatic strategies to identify treatment candidates in routine practice. We assessed the real‐world applicability of the AISF STEPS‐MASH algorithm and characterised the treatment status of people reaching final assessment in tertiary hepatology centres. Methods: We retrospectively applied the AISF STEPS‐MASH algorithm to all consecutive adults undergoing vibration‐controlled transient elastography (VCTE) at nine Italian tertiary hepatology centres between January and June 2025. Step S defined a broad screening pool (controlled attenuation parameter [CAP] ≥ 248 dB/m and/or a metabolic referral indication). People with CAP‐defined steatosis, at least one cardiometabolic risk factor or metabolic referral indication, and no documented competing liver disease aetiology were assigned to the Primary pathway; all others were analysed separately as the Non‐primary pathway. Step T applied liver stiffness measurement (LSM) ≥ 8.0 kPa, excluding LSM ≥ 20.0 kPa and/or platelet count < 150 × 10 ⁹ /L. Step E classified safety‐related conditions as label‐defined contraindications, warnings requiring monitoring, or interactions requiring treatment modification or temporary deferral. Stepwise attrition across Steps S, T and E was quantified. Results: Of 8194 people screened, 8150 (99.5%) had paired CAP and LSM data. Step S criteria were met by 4371 (53.6%), of whom 2300 entered the Primary pathway and 2071 the Non‐primary pathway. Initial Step T criteria were met by 1041 people (23.8% of Step S; 12.8% of the evaluable cohort), and 750 reached the final Step T population after excluding 291 people with LSM ≥ 20.0 kPa and/or thrombocytopenia: 458 Primary and 292 Non‐primary. Within the final Step T Primary pathway, 317 people (69.2%) had a treatment status compatible with both drugs without modification, 140 (30.6%) required medication or clinical optimisation, and one (0.2%) had a formal contraindication. The Non‐primary pathway contained an adjudication reservoir of 191 people with an operational MASLD phenotype and a competing aetiology. The final Step T Primary pathway corresponded to 56.2 people per 1000 evaluable VCTE examinations, approximately one in every 18. Conclusions: In tertiary hepatology practice, the AISF STEPS‐MASH algorithm translated broad VCTE activity into a focused treatment‐assessment population. Nearly one third of those assessed required medication or clinical optimisation before treatment, a proportion likely to vary across clinical settings, and the pathway also identified people requiring advanced liver disease surveillance or aetiological adjudication.

doi.org/10.1111/liv.70956Open accessBiomarkers

AgingResearch.News